Table 2.
A selection of target analytes for MIP-based sensors aiming at therapeutic drug monitoring.
| Drug | Linear Range | LOD | Complex Matrix | Recovery Rate [%] | Reference |
|---|---|---|---|---|---|
| metronidazole | 50–1200 ng/mL (PBS) | 17.4 ng/mL (PBS) | Human serum | 93.5–102.7 | [58] |
| velpatasvir | 0.649–80.0 ng/mL (phosphate buffer) |
0.21 ng/mL (phosphate buffer) |
Plasma and urine | 101.2–101.5 | [59] |
| insulin | 50–2000 pM (plasma) | 0.081 pM | plasma | 99.5–101 | [61] |
| puerarin | 0.02–40 µM | 0.006 µM | urine | 96.7–102.9 | [62] |
| cytarabine | 1.0 × 10−6–1.0 × 10−3 M (phosphate buffer) | 5.5 × 10−7 (phosphate buffer) |
Human serum and urine | 98.6–99.1 (urine) 95.3–103 (serum) |
[63] |
| azithromycin | 13.33 nM–66.66 µM | 0.85 nM | Plasma, urine and tears | 102.4 (plasma) 98.03–106.33 (urine) 99.06–109.88 (tears) |
[64] |
| oxaliplatin | 1.0–20.0 nM 20.0–250.0 nM |
0.39 nM (serum) 0.41 nM (urine) |
Human serum and urine | 95.7–106.9 (serum) 94.6–108.3 (urine) |
[65] |